In addition to internal R&D, Chlitina carries out research projects in partnership with Chia Nan University of Pharmacy and Science in southern Taiwan’s Tainan City and the Biomedical Technology and Device Research Laboratories under the government-supported Industrial Technology Research Institute in the northern county of Hsinchu. Related initiatives span clinical trials as well as studies of plant extracts for skin whitening properties. And in 2015, it established a subsidiary in Paris to facilitate collaboration with France Lab, part of the Marie Claire Group, on product development.
Next on the expansion agenda for Chlitina is Southeast Asia. In January, the company opened its first branch in Vietnam and plans are in the works for outlets in Cambodia, Indonesia and Myanmar. “Young populations and emerging middle classes are fueling sales growth in ASEAN markets,” Kao said. “And health, beauty and wellness is one of the most popular spending categories among these groups.”
According to the general manager, efforts to boost commercial ties with the region are also in line with the New Southbound Policy (NSP). A key plank of the government’s national development strategy, the NSP seeks to deepen Taiwan’s agricultural, business, cultural, education, tourism and trade links with the 10 Association of Southeast Asian Nations member states, six South Asian countries, Australia and New Zealand.
“Owing to our technological know-how and extensive business development experience, I’m confident we can make successful inroads into emerging regional markets,” he said. “Eventually, we aim to gain a strong foothold worldwide.”